Researchers from the US have developed CARMEN - a miniaturised, scalable and highly-multiplexed nucleic acid detection assay that uses CRISPR-Cas13 technology. The hope is that this assay can be used for rapid disease surveillance - timely given the current COVID-19 pandemic!
Editas Medicine is getting ready to submit an IND for EDIT-201, an allogeneic natural killer cell therapy for solid tumour cancers. The company uses CRISPR technology to develop novel cell therapies and plans to release preclinical data on EDIT-201 later this year.
CRISPR-Cas9-edited patient-derived stem cells successfully reverse diabetes in mice. In case you missed it, you can find our interview with the lead researcher here.
We came across a useful tracking resource that allows you to see which human/health products and processes related to gene editing are approved or in development and their regulatory status. You can check it out here.